Published

Neuro Startup Nura Bio Adds $68M to Spare Axons With Its Brain-Penetrating Drug

Summary by MedCity News
Nura Bio aims to treat neurodegeneration with a small molecule designed to block SARM1, a novel target involved in axon degeneration. Following positive Phase 1 results in healthy volunteers, the startup is now preparing for mid-stage clinical testing. The post Neuro Startup Nura Bio Adds $68M to Spare Axons With Its Brain-Penetrating Drug appeared first on MedCity News.

0 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)